Abstract
In the January 2024 issue of Thyroid (vol. 34, no. 1; pp. 26–40) the article entitled “Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study” by Subbiah et al. requires correction.
This article was originally published under the copyright of Mary Ann Liebert, Inc. publishers. It has now been updated to reflect Open Access, with copyright transferring to the author(s), and a Creative Commons License (CC-BY) added (http://creativecommons.org/licenses/by/4.0). The CC-BY license goes into effect April 16, 2024.
The online version of this article has been corrected to reflect this.